[{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"0dde1fb8-86ca-42a7-8591-8335a74747cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT00045201","created_at":"2021-01-18T00:03:58.280Z","updated_at":"2025-02-25T13:51:49.237Z","phase":"Phase 1","brief_title":"Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT00045201","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["EGFR • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/13/2002","start_date":" 06/13/2002","primary_txt":" Primary completion: 09/13/2013","primary_completion_date":" 09/13/2013","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2025-02-20"},{"id":"4e9825d2-8606-4a5c-bf4c-e0714ac9fa73","acronym":"GO42144","url":"https://clinicaltrials.gov/study/NCT04449874","created_at":"2021-01-18T21:24:33.964Z","updated_at":"2025-02-25T14:40:37.769Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","source_id_and_acronym":"NCT04449874 - GO42144","lead_sponsor":"Genentech, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • erlotinib • divarasib (RG6330) • Itovebi (inavolisib) • migoprotafib (RLY-1971)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-14"},{"id":"a58385e3-f746-48dd-bf8f-10d8e83d28bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01708954","created_at":"2021-01-18T07:26:37.698Z","updated_at":"2025-02-25T16:36:12.668Z","phase":"Phase 2","brief_title":"Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01708954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • RET","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion","tags":["HER-2 • KRAS • BRAF • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 02/13/2013","start_date":" 02/13/2013","primary_txt":" Primary completion: 08/14/2015","primary_completion_date":" 08/14/2015","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"f728f5a5-7b35-4430-bcb8-753e01deecd0","acronym":"ALCHEMIST","url":"https://clinicaltrials.gov/study/NCT02193282","created_at":"2021-01-18T10:14:33.510Z","updated_at":"2025-02-25T16:43:51.158Z","phase":"Phase 3","brief_title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","source_id_and_acronym":"NCT02193282 - ALCHEMIST","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 02/11/2015","start_date":" 02/11/2015","primary_txt":" Primary completion: 10/10/2026","primary_completion_date":" 10/10/2026","study_txt":" Completion: 10/10/2026","study_completion_date":" 10/10/2026","last_update_posted":"2025-02-06"},{"id":"45b9e4e8-9732-4ed9-b569-eae18917beb8","acronym":"KEYNOTE E27","url":"https://clinicaltrials.gov/study/NCT04956640","created_at":"2021-07-09T12:57:24.328Z","updated_at":"2025-02-25T16:16:26.190Z","phase":"Phase 1/2","brief_title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","source_id_and_acronym":"NCT04956640 - KEYNOTE E27","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-28"},{"id":"613dfa54-e318-471f-a8ed-a12b2572968b","acronym":"CAPTUR","url":"https://clinicaltrials.gov/study/NCT03297606","created_at":"2021-01-18T16:17:30.914Z","updated_at":"2025-02-25T13:52:23.697Z","phase":"Phase 2","brief_title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","source_id_and_acronym":"NCT03297606 - CAPTUR","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-11-12"},{"id":"6f4faf68-b16d-468b-9596-4d2ec114a446","acronym":"","url":"https://clinicaltrials.gov/study/NCT02364609","created_at":"2021-01-18T11:15:31.840Z","updated_at":"2025-02-25T16:14:29.149Z","phase":"Phase 1","brief_title":"Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib","source_id_and_acronym":"NCT02364609","lead_sponsor":"Jonathan Riess","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • erlotinib • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2024-10-16"},{"id":"03fa7b60-29a0-4a44-aa05-14a8b5df45eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02091141","created_at":"2021-01-17T17:15:36.027Z","updated_at":"2025-02-25T12:26:06.921Z","phase":"Phase 2","brief_title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02091141","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 673","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-07-23"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"ea2426dc-fd65-4541-b437-a3fa2dace5ba","acronym":"Promise","url":"https://clinicaltrials.gov/study/NCT06081907","created_at":"2023-10-14T01:13:10.291Z","updated_at":"2024-07-02T16:35:00.048Z","phase":"Phase 1/2","brief_title":"The Efficacy and Safety of IBI363 in Solid Tumors","source_id_and_acronym":"NCT06081907 - Promise","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • HER-2 • PD-L1 • BRAF • ALK • RET • CD73 • NTRK","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation","tags":["EGFR • HER-2 • PD-L1 • BRAF • ALK • RET • CD73 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 12/25/2023","start_date":" 12/25/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-05-30"},{"id":"42d098db-7735-4ec6-beca-081467347e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00254384","created_at":"2021-01-18T00:51:46.726Z","updated_at":"2024-07-02T16:35:01.822Z","phase":"Phase 1","brief_title":"Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery","source_id_and_acronym":"NCT00254384","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • erlotinib • docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/05/2005","start_date":" 10/05/2005","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2024-05-23"},{"id":"793b612f-f72f-4afe-b67d-aade9074d23c","acronym":"JUNIPER","url":"https://clinicaltrials.gov/study/NCT02152631","created_at":"2021-01-17T17:34:33.385Z","updated_at":"2024-07-02T16:35:08.915Z","phase":"Phase 3","brief_title":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","source_id_and_acronym":"NCT02152631 - JUNIPER","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 453","initiation":"Initiation: 10/03/2014","start_date":" 10/03/2014","primary_txt":" Primary completion: 09/15/2017","primary_completion_date":" 09/15/2017","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-18"},{"id":"90e2c2df-d5c6-4f93-8b0d-0ff266e30b82","acronym":"","url":"https://clinicaltrials.gov/study/NCT01306045","created_at":"2021-01-18T05:18:49.422Z","updated_at":"2024-07-02T16:35:10.788Z","phase":"Phase 2","brief_title":"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","source_id_and_acronym":"NCT01306045","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • sunitinib • lapatinib • Koselugo (selumetinib) • MK-2206"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 647","initiation":"Initiation: 02/08/2011","start_date":" 02/08/2011","primary_txt":" Primary completion: 02/12/2014","primary_completion_date":" 02/12/2014","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-09"},{"id":"996b1b43-b82a-40c0-864e-b24143f66b75","acronym":"","url":"https://clinicaltrials.gov/study/NCT03076164","created_at":"2021-01-18T15:09:20.196Z","updated_at":"2025-02-25T13:12:15.548Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib","source_id_and_acronym":"NCT03076164","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 12/18/2020","primary_completion_date":" 12/18/2020","study_txt":" Completion: 12/18/2020","study_completion_date":" 12/18/2020","last_update_posted":"2024-04-02"},{"id":"5f952e53-c94e-4072-b418-d6bed213f5a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02273362","created_at":"2021-01-18T10:41:42.315Z","updated_at":"2024-07-02T16:35:12.899Z","phase":"Phase 1/2","brief_title":"Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver","source_id_and_acronym":"NCT02273362","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • EGF • PCNA","pipe":" | ","alterations":" EGFR positive","tags":["EGFR • EGF • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/24/2014","start_date":" 11/24/2014","primary_txt":" Primary completion: 02/11/2020","primary_completion_date":" 02/11/2020","study_txt":" Completion: 03/10/2022","study_completion_date":" 03/10/2022","last_update_posted":"2024-03-26"},{"id":"53d80059-10cf-4b1e-809f-d51433276602","acronym":"RELAY","url":"https://clinicaltrials.gov/study/NCT02411448","created_at":"2021-01-17T17:40:04.195Z","updated_at":"2024-07-02T16:35:14.291Z","phase":"Phase 3","brief_title":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","source_id_and_acronym":"NCT02411448 - RELAY","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 545","initiation":"Initiation: 05/06/2015","start_date":" 05/06/2015","primary_txt":" Primary completion: 01/23/2019","primary_completion_date":" 01/23/2019","study_txt":" Completion: 12/16/2024","study_completion_date":" 12/16/2024","last_update_posted":"2024-03-18"},{"id":"b2ee5075-c228-40d0-b9ee-e5526535926f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00878163","created_at":"2021-01-18T03:21:25.984Z","updated_at":"2024-07-02T16:35:15.360Z","phase":"Phase 1","brief_title":"GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00878163","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gemcitabine • Erivedge (vismodegib) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2009","start_date":" 03/31/2009","primary_txt":" Primary completion: 01/22/2013","primary_completion_date":" 01/22/2013","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-03-11"},{"id":"d448b93f-39b9-4496-9d25-48f1c9adcfa3","acronym":"Balise","url":"https://clinicaltrials.gov/study/NCT01897480","created_at":"2021-01-18T08:31:57.339Z","updated_at":"2024-07-02T16:35:16.757Z","phase":"Phase 2","brief_title":"A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations","source_id_and_acronym":"NCT01897480 - Balise","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • emibetuzumab (LY2875358)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 08/28/2013","start_date":" 08/28/2013","primary_txt":" Primary completion: 03/14/2016","primary_completion_date":" 03/14/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-01"},{"id":"3764281d-c032-461a-9654-0d441d63c924","acronym":"","url":"https://clinicaltrials.gov/study/NCT02098954","created_at":"2021-01-18T09:41:28.217Z","updated_at":"2024-07-02T16:35:25.065Z","phase":"Phase 2","brief_title":"Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers","source_id_and_acronym":"NCT02098954","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • erlotinib • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/12/2025","study_completion_date":" 12/12/2025","last_update_posted":"2023-12-27"},{"id":"7218e546-77ae-4326-92dc-2bfe9ec5ace3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03647592","created_at":"2021-01-18T17:54:17.426Z","updated_at":"2024-07-02T16:35:25.192Z","phase":"","brief_title":"Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03647592","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • erlotinib • gefitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-27"},{"id":"7d41bb5c-8775-4bbb-9bda-315d6ca7d0d0","acronym":"SELECT-2","url":"https://clinicaltrials.gov/study/NCT04401059","created_at":"2023-12-27T18:16:50.631Z","updated_at":"2024-07-02T16:35:25.073Z","phase":"Phase 4","brief_title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","source_id_and_acronym":"NCT04401059 - SELECT-2","lead_sponsor":"Tian Xie","biomarkers":" EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR positive","tags":["EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 744","initiation":"Initiation: 11/09/2020","start_date":" 11/09/2020","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2023-12-27"},{"id":"0c2fb334-77f1-4029-be43-81d7daa28234","acronym":"BLISS","url":"https://clinicaltrials.gov/study/NCT05081674","created_at":"2021-10-18T12:53:11.083Z","updated_at":"2024-07-02T16:35:33.886Z","phase":"Phase 2","brief_title":"Brazilian Lung Immunotherapy Study","source_id_and_acronym":"NCT05081674 - BLISS","lead_sponsor":"Hospital Israelita Albert Einstein","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • erlotinib • carboplatin • docetaxel • Alecensa (alectinib)"],"overall_status":"Completed","enrollment":" Enrollment 154","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 07/30/2023","study_completion_date":" 07/30/2023","last_update_posted":"2023-10-11"},{"id":"598803d8-3689-4dfe-841d-604c784e799c","acronym":"ARCTIC","url":"https://clinicaltrials.gov/study/NCT02352948","created_at":"2021-01-17T17:12:52.779Z","updated_at":"2024-07-02T16:35:33.908Z","phase":"Phase 3","brief_title":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","source_id_and_acronym":"NCT02352948 - ARCTIC","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Imfinzi (durvalumab) • gemcitabine • Imjudo (tremelimumab-actl) • vinorelbine tartrate"],"overall_status":"Completed","enrollment":" Enrollment 597","initiation":"Initiation: 01/13/2015","start_date":" 01/13/2015","primary_txt":" Primary completion: 02/09/2018","primary_completion_date":" 02/09/2018","study_txt":" Completion: 08/30/2023","study_completion_date":" 08/30/2023","last_update_posted":"2023-10-11"}]